High-dose nevirapine in previously untreated human immunodeficiency virus type 1-infected persons does not result in sustained suppression of viral replication

Journal of Infectious Diseases

Volumn 175, Issue 4, 1997, Pages 966-970

  De Jong, M D ^a   Vella, S ^c   Carr, A ^c   Boucher, C A B ^b   Imrie, A ^c   French, M ^c   Hoy, J ^c   Sorice, S ^c   Pauluzzi, S ^c   Chiodo, F ^c   Weverling, G J ^c   Van Der Ende, M E ^c   Frissen, Ph J ^c   Weigel, H M ^c   Kauffmann, R H ^c   Lange, J M A ^c   Yoon, R ^c   Moroni, M ^c   Hoenderdos, E ^c   Leitz, G ^c   Cooper, D A ^c   Hall, D ^c   Reiss, P ^c   more..

^a ACADEMIC MEDICAL CENTER   (Netherlands)

^b UTRECHT UNIVERSITY   (Netherlands)

^c NONE

Author keywords

[No Author keywords available]

Indexed keywords

NEVIRAPINE;

ANTIVIRAL ACTIVITY; ARTICLE; CLINICAL ARTICLE; DRUG BLOOD LEVEL; DRUG EFFICACY; FEVER; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; PRIORITY JOURNAL; RASH; TREATMENT OUTCOME; VIRUS REPLICATION;

EID: 16944364799     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/514002     Document Type: Article

References (15)

1. Cheeseman SH, Havlir D, McLaughlin MM, et al. Phase I/II evaluation of nevirapine alone and in combination with zidovudine for infection with human immunodeficiency virus. J Acquir Immune Defic Syndr 1995;8:141-51.
2. Richman DD, Havlir D, Corbeil J, et al. Nevirapine resistance mutations of human immunodeficiency virus type I selected during therapy. J Virol 1994;68:1660-6.
3. De Jong MD, Loewenthal M, Boucher CAB, et al. Alternating nevirapine and zidovudine treatment of human immunodeficiency virus type 1-infected persons does not prolong nevirapine activity. J Infect Dis 1994;169:1346-50.
4. Havlir D, Cheeseman SH, McLaughlin M, et al. High-dose nevirapine: safety, pharmacokinetics, and antiviral effect in patients with human immunodeficiency virus infection. J Infect Dis 1995;171:537-45.
5. Cheeseman SH, Murphy LR, Saag MS, Havlir D. Safety of high dose nevirapine (nvp) after 200 mg/d lead-in [abstract]. In: Program and abstracts: IX International Conference on AIDS/IV STD World Congress (Berlin). London: Wellcome Foundation, 1993.
6. Mulder J, McKinney N, Christopherson C, Sninsky J, Greenfield L, Kwok S. Rapid and simple PCR assay for quantification of human immunodeficiency virus type 1 RNA in plasma: application to acute retroviral infection. J Clin Microbiol 1994;32:292-300.
7. Kaye S, Loveday C, Tedder RS. A microtiter format point mutation assay: application to the detection of drug resistance in human immunodefi-ciency virus type 1-infected patients treated with zidovudine. J Med Virol 1992;37:241-6.
8. Jayaraj A, Alexander J, Price C. A rapid and sensitive HPLC-UV method for the quantitation of an anti-HIV agent, nevirapine and its solid-phase extractable metabolites in biological fluids. Pharm Res 1992;9:S334.
9. Hill AM. CD4 rises during anti-HIV treatment: statistical artefact? AIDS 1994;8:S3.
10. 3: AIDS Clinical Trials Group Protocol 208. J Infect Dis 1995;172:1379-83.
11. Carr A, Vella S, De Jong MD, et al. A controlled trial of nevirapine plus zidovudine versus zidovudine alone in p24 antigenemic HIV-infected patients. AIDS 1996;10:635-41.
12. Emini EA. HIV-I protease inhibitors [abstract]. In: Proceedings of the 3rd National Conference on Retroviruses and Opportunistic Infections, Washington, DC, 1996.
13. Brown AE, Vahey MT, Zhou SYJ, et al. Quantitative relationship of circulating p24 antigen with human immunodeficiency virus (HIV) RNA and specific antibody in HIV-infected subjects receiving antiretroviral therapy. J Infect Dis 1995;172:1091-5.
14. D'Aquila RT, Hughes MD, Johnson VA, et al. Nevirapine, zidovudine, and didanosine compared with zidovudine and didanosine in patients with HIV-1 infection. Ann Intern Med 1996;124:1019-30.
15. 3 [abstract]. In: Program and abstracts: XI International Conference on AIDS (Vancouver). Vancouver, Canada: XI International Conference on AIDS Society, 1996.